FDA Approves Merck's New Drug For A Rare Lung Disease

The pharmaceutical giant’s new treatment, sotatercept, showed significant benefits for the thousands of patients suffering from pulmonary arterial hypertension in clinical trials.

Related Keywords

United States ,Americans ,Panagis Galiatsatos ,Eliav Barr ,Johns Hopkins School Of Medicine ,Drug Administration ,Johns Hopkins School ,New England Journal ,New Medication To Prevent ,Common Hospital ,Fda ,Food And Drug Administration ,Merck ,Pulmonary Arterial Hypertension ,Pah ,Sotatercept ,Winrevair ,Lung Disease ,